How Does Growth Hormone Work? Mechanism of Action in the Literature

The short answer: a cytokine-type receptor and a kinase cascade

Growth hormone (GH, somatotropin) is a single-chain peptide secreted by somatotroph cells of the anterior pituitary. Its molecular target is the growth hormone receptor (GHR), a member of the class I cytokine receptor superfamily that has no intrinsic kinase activity of its own; a review of GH signal transduction described how hormone binding drives receptor dimerisation and a conformational change that brings two molecules of the associated tyrosine kinase JAK2 into proximity so they can trans-phosphorylate each other (PMID 12099386). A 2021 review of JAK2-mediated intracellular signalling summarised how activated JAK2 phosphorylates tyrosine residues on the receptor tail, creating docking sites for STAT transcription factors and other adaptors that carry the signal to the nucleus (PMID 33059575).

Everything else commonly described as a "growth hormone effect" sits downstream of that single step: either direct GHR signalling in a target tissue, or indirect signalling through insulin-like growth factor 1 (IGF-1) generated in response to GHR activation. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment. It describes mechanism as published and contains no dosing, protocol or outcome guidance.

Upstream: what controls growth hormone release

GH secretion is pulsatile and sits under dual hypothalamic control — growth hormone-releasing hormone (GHRH) stimulating release and somatostatin restraining it. A third input is the ghrelin system: a 2023 review of the ghrelin system described ghrelin acting at the growth hormone secretagogue receptor (GHS-R1a), the same receptor family targeted by synthetic secretagogues, and discussed its signalling beyond somatotrophs in the central nervous system (PMID 36527939). That distinction matters mechanistically: secretagogues act one step upstream, on the cells that release GH, whereas GH itself acts on GHR in peripheral tissues.

The pituitary is not the only source described in the literature. A review of extrapituitary growth hormone reported GH gene expression and peptide production in tissues including immune cells, reproductive tissue, the nervous system and the gastrointestinal tract, where researchers proposed autocrine and paracrine roles distinct from classical endocrine signalling (PMID 20972718). Local, non-circulating GH is therefore part of the published mechanistic picture, although the review framed much of its physiological significance as still being characterised.

The receptor step in detail

The GHR is a transmembrane protein with an extracellular hormone-binding domain, a single membrane-spanning segment and an intracellular tail. The classical model is one GH molecule engaging two receptor subunits through two distinct binding sites; the review of GH signal transduction described the functional consequence as a repositioning of pre-associated receptor subunits rather than simple recruitment of two separate monomers, with JAK2 activation as the first measurable event (PMID 12099386). The extracellular domain is also shed as GH-binding protein, which circulates bound to GH.

Evidence that the receptor is the obligatory gateway comes largely from genetics and from animal models. A 2021 review of mouse models of growth hormone insensitivity summarised strains in which GHR or its signalling partners were disrupted and described the resulting phenotypes as a mirror of human GH insensitivity, where circulating GH is present but downstream signalling is impaired (PMID 33037595). These are animal models, and the review treated them as tools for dissecting the pathway rather than as direct statements about human physiology.

Intracellular signalling branches

Once JAK2 is active, published work describes several parallel branches rather than a single linear pathway. The JAK2 review grouped the principal outputs as STAT activation, the RAS–MAPK/ERK cascade and the PI3K–AKT axis, and noted that JAK2 signalling is shared with other cytokine and hormone receptors, which is why pathway specificity depends heavily on receptor context and on the cell type involved (PMID 33059575). The GH signal transduction review described STAT5b in particular as the transcription factor most closely tied to GH-dependent gene expression, and described suppressor of cytokine signalling (SOCS) proteins as an inducible brake that terminates the signal after a pulse (PMID 12099386).

The IGF-1 arm: direct versus indirect action

A central feature of GH pharmacology is that part of its action is relayed. GHR activation in the liver increases transcription and secretion of IGF-1, which then acts on its own receptor in peripheral tissues. A 2020 review integrating growth hormone, testosterone, IGFs and cortisol described the GH–IGF-1 axis as a coordinated hormonal network for cellular development and growth, and reported that exercise is one of the physiological stimuli that perturbs these hormones together rather than in isolation (PMID 32158429). That review emphasised that circulating measurements of any one hormone do not map cleanly onto tissue-level signalling.

Liver biology provides a second window on the same arm. A 2023 review of hepatocyte growth regulators in liver regeneration described the networks of growth factors, cytokines and hormonal inputs that govern hepatocyte proliferation and the return to quiescence, placing growth-regulatory signalling in the liver within a tightly controlled sequence rather than a simple on-switch (PMID 36672143).

Tissue-specific evidence from knockout mice

Because the liver, muscle, fat and bone all express GHR, separating direct from IGF-1-mediated effects required conditional genetics. A 2020 updated review of tissue-specific GHR knockout mice summarised strains in which the receptor was deleted from individual tissues and reported that the metabolic and growth phenotypes differed by tissue, supporting the idea that GH exerts distinct local actions in addition to driving hepatic IGF-1 output (PMID 33162937). These findings are rodent findings and the review presented them as mechanistic dissection, not as a model of clinical response.

Downstream physiology as described in the literature

Bone and the growth plate

Longitudinal growth and bone turnover are two separate processes. A 2018 review of the bone remodelling cycle described the coupled sequence of osteoclast-mediated resorption followed by osteoblast-mediated formation, regulated by the RANK/RANKL/osteoprotegerin system and by systemic hormonal input (PMID 29368538). In a disease context where growth is impaired for reasons other than GH deficiency, a 2020 review of X-linked hypophosphataemic rickets discussed growth impairment and the place of growth-promoting strategies in that specific genetic condition (PMID 32236870). The mechanistic point researchers drew is that GH signalling is one of several inputs to the growth plate, and mineral handling defects can limit growth independently of the GH axis.

Muscle, body composition and metabolism

The integrative review of GH, testosterone, IGFs and cortisol described these hormones as acting on overlapping intracellular pathways in muscle, with signalling and receptor sensitivity — not just hormone concentration — determining the cellular response (PMID 32158429). On the metabolic side, the tissue-specific GHR knockout review reported that removing the receptor from individual metabolic tissues produced distinct effects on adiposity and insulin-related measures in mice (PMID 33162937).

Ageing biology

Two reviews in the same journal examined the GH axis in ageing. A 2019 updated review of growth hormone and ageing described the age-related decline in GH secretion (sometimes called somatopause) and discussed the interpretation of that decline, while cautioning that the relationship between the GH axis and ageing is not a simple deficit model (PMID 29756419). A 2021 follow-up review on new findings in growth hormone and ageing revisited the same axis in light of newer data and continued to frame the area as unresolved (PMID 33663025).

Established mechanism versus proposed mechanism

It helps to separate what is textbook pharmacology from what is still hypothesis.

• Established: GH binds GHR, a class I cytokine receptor lacking intrinsic kinase activity, and signals through JAK2 (PMID 12099386).
• Established: JAK2 activation recruits STAT, MAPK and PI3K branches, with SOCS proteins acting as inducible negative feedback (PMID 33059575).
• Established in animals: deleting GHR globally or in single tissues produces distinct growth and metabolic phenotypes in mice (PMID 33162937, PMID 33037595).
• Proposed: locally produced extrapituitary GH acting in autocrine/paracrine fashion with functions distinct from circulating GH (PMID 20972718).
• Proposed and contested: the significance of age-related changes in GH secretion for ageing biology, which reviews described as unresolved (PMID 33663025, PMID 29756419).

Mechanism-Linked Effects: What Studies Report

Mechanism pages are not safety pages, and the papers cited here are predominantly reviews of signalling and animal genetics rather than clinical safety studies. What the verified literature does report is that GH signalling is pleiotropic: the tissue-specific GHR knockout review reported that the same receptor produces different outcomes depending on which tissue it is removed from, so effects in one organ system cannot be assumed to generalise (PMID 33162937). Because the PI3K/AKT branch intersects with insulin signalling, the JAK2 review described metabolic crosstalk as an intrinsic feature of the pathway rather than an off-target quirk (PMID 33059575). Reviews of growth hormone and ageing discussed the need for caution in extrapolating from axis physiology to intervention (PMID 29756419). Anyone with a clinical question should raise it with a licensed physician.

Reading further

For background on the hormone itself — nomenclature, regulatory status of approved products, and what the broader evidence base covers — see the overview at /learn/growth-hormone/. This page covers mechanism only and deliberately states no doses, schedules or expected results.

References

• Growth hormone signal transduction (Journal of Pediatric Endocrinology & Metabolism, 2002)
• JAK2-mediated Intracellular Signaling (Current Molecular Medicine, 2021)
• Ghrelin system in Alzheimer's disease (Current Opinion in Neurobiology, 2023)
• Extrapituitary growth hormone (Endocrine, 2010)
• Mouse models of growth hormone insensitivity (Reviews in Endocrine & Metabolic Disorders, 2021)
• Tissue-Specific GHR Knockout Mice: An Updated Review (Frontiers in Endocrinology, 2020)
• Role of Hepatocyte Growth Regulators in Liver Regeneration (Cells, 2023)
• Growth Hormone(s), Testosterone, Insulin-Like Growth Factors, and Cortisol: Roles and Integration for Cellular Development and Growth With Exercise (Frontiers in Endocrinology, 2020)
• The bone remodelling cycle (Annals of Clinical Biochemistry, 2018)
• X-Linked Hypophosphataemic Rickets and Growth (Advances in Therapy, 2020)
• Growth Hormone and Aging: Updated Review (The World Journal of Men's Health, 2019)
• Growth Hormone and Aging: New Findings (The World Journal of Men's Health, 2021)